Longitudinal follow-up of metformin treatment in Fragile X Syndrome
Frontiers in Psychology · 13.06.2024 · 15
DOI: 10.3389/fpsyg.2024.1305597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Psychology, online erschienen am 13.06.2024. Verfasst von Panhaneath Seng und 14 weiteren Autor:innen. Beteiligte Einrichtung: MIND Institute, University of California Davis Health System, Sacramento, CA, United States. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
Introduction
Metformin has been used as a targeted treatment to potentially improve cognition and slow the typical IQ decline that occurs during development among individuals with fragile X syndrome (FXS). In this follow-up study, we are following the trajectory of IQ and adaptive behavior changes over 1 to 3 years in individuals with FXS who are clinically treated with metformin in an open label trial.
Method
Individuals with FXS ages 6 to 25 years (mean 13.15 ± 5.50) and nonverbal IQ mean 57.69 (±15.46) were treated for 1–3 years (1.88 ± 0.63). They all had a baseline IQ test using the Leiter-III non-verbal cognitive assessment and the Vineland-III adaptive behavior assessment before the start of metformin. Repeat Leiter-III and Vineland-III were completed after at least 1 year of metformin (500–1,000 mg/dose given twice a day).
Result
There were no significant changes in non-verbal IQ or in the adaptive behavior measurements at FDR < 0.05. The findings thus far indicate that both IQ and adaptive behavior are stable over time, and we did not see a significant decline in either measure.
Conclusion
Overall, the small sample size and short follow-up duration limit the interpretation of the effects of metformin on cognitive development and adaptive functioning. There is individual variability but overall for the group there was no significant decline in IQ or adaptive behavior.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MIND Institute, University of California Davis Health System, Sacramento, CA, United States.
- Child and Adolescent Neuropsychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Department of Education, Psychology, Communication, University of Bari Aldo Moro, Bari, Italy.
- Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, United States.
- Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento, CA, United States.
- Integrative Genetics and Genomics Graduate Group, University of California Davis, Davis, CA, United States.
Förderung
- NICHD NIH HHS
Zitieren
APA
Seng, P., Montanaro, F. A. M., Biag, H. M. B., Salcedo-Arellano, M. J., Kim, K., Ponzini, M. D., Tassone, F., Schneider, A., Abbeduto, L., Thurman, A. J., Hessl, D., Bolduc, F. V., Jacquemont, S., Lippé, S., & Hagerman, R. J. (2024). Longitudinal follow-up of metformin treatment in Fragile X Syndrome. Frontiers in Psychology, 15. https://doi.org/10.3389/fpsyg.2024.1305597
Vancouver
Seng P, Montanaro FAM, Biag HMB, Salcedo-Arellano MJ, Kim K, Ponzini MD, et al. Longitudinal follow-up of metformin treatment in Fragile X Syndrome. Frontiers in Psychology. 2024;15. doi:10.3389/fpsyg.2024.1305597
BibTeX
@article{Seng2024,
author = {Seng, Panhaneath and Montanaro, Federica Alice Maria and Biag, Hazel Maridith Barlahan and Salcedo-Arellano, Maria Jimena and Kim, Kyoungmi and Ponzini, Matthew Dominic and Tassone, Flora and Schneider, Andrea and Abbeduto, Leonard and Thurman, Angela John and Hessl, David and Bolduc, Francois V and Jacquemont, Sebastien and Lippé, Sarah and Hagerman, Randi J},
title = {Longitudinal follow-up of metformin treatment in Fragile X Syndrome},
journal = {Frontiers in Psychology},
year = {2024},
volume = {15},
doi = {10.3389/fpsyg.2024.1305597}
}
EUVIMED